Targeting toll-like receptors for drug development: a summary of commercial approaches (Q36898653)

16 August 2017

1 reference

title

Targeting toll-like receptors for drug development: a summary of commercial approaches (English)

1 reference

16 August 2017

0 references

Andrew J H Gearing

1

1 reference

16 August 2017

31 July 2007

1 reference

Immunology & Cell Biology

16 August 2017

1 reference

16 August 2017

85

1 reference

16 August 2017

6

1 reference

16 August 2017

490-494

1 reference

Pathogen recognition and innate immunity

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

'Toll' gates for future immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Ligand-induced conformational changes allosterically activate Toll-like receptor 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Cooperation of Toll-like receptor signals in innate immune defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Activation of the mammalian immune system by siRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

How Toll-like receptors signal: what we know and what we don't know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The role of toll-like receptors in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Activation of the innate immune system in atherosclerotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The role of Toll-like receptor signalling in the pathogenesis of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

The role of innate immunity in asthma: leads and lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

TLR9-based immunotherapy for allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Update on toll-like receptor ligands and allergy: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Therapeutic targeting of toll-like receptors in gastrointestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

TLR2 has a detrimental role in mouse transient focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

Viral and nonviral uses of imiquimod: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Immunology. Targeting the tolls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ICB.7100102

7 January 2021

Identifiers

DOI

10.1038/SJ.ICB.7100102

1 reference

16 August 2017

1 reference

PubMed ID

17667933